Estradiol valerate and dienogest

A novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding

Elizabeth Micks, Jeffrey Jensen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an estrogen component that is biologically active as the endogenous estrogen 17β-estradiol. This medication was developed out of efforts to replace the most common estrogen in contraceptive pills, ethinyl estradiol, which is known to be a potent inducer of hepatic protein synthesis. Estradiol valerate has been available since the 1970s in oral and injectable forms indicated for the treatment of menopausal climacteric symptoms. Dienogest has been used in other oral contraceptive pills for over 10 years. Previous attempts to develop an oral contraceptive pill with natural estradiol or estradiol valerate were unsuccessful due to poor cycle control. A novel dynamic-dosing regimen was devised to improve the bleeding pattern. This medication has been shown in several clinical trials to have good contraceptive efficacy and cycle control. Recent studies have also demonstrated that this medication is effective for the treatment of heavy menstrual bleeding. However, compared with other oral contraceptive pills, this medication is associated with a higher frequency of absent withdrawal bleeding. Furthermore, the dynamic dosing regimen requires relatively complex instructions for users who miss pills.

Original languageEnglish (US)
Pages (from-to)513-524
Number of pages12
JournalWomen's Health
Volume7
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Oral Contraceptives
estradiol valerate
Hemorrhage
Pregnancy
Estrogens
dienogest
Contraceptive Agents
Estradiol
Therapeutics
Ethinyl Estradiol
estradiol valerate-dienogest
Clinical Trials
Injections
Liver
Proteins

Keywords

  • contraception
  • dienogest
  • estradiol valerate
  • heavy menstrual bleeding
  • menorrhagia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{820e68905a3040efb94d96ac7068e19f,
title = "Estradiol valerate and dienogest: A novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding",
abstract = "Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an estrogen component that is biologically active as the endogenous estrogen 17β-estradiol. This medication was developed out of efforts to replace the most common estrogen in contraceptive pills, ethinyl estradiol, which is known to be a potent inducer of hepatic protein synthesis. Estradiol valerate has been available since the 1970s in oral and injectable forms indicated for the treatment of menopausal climacteric symptoms. Dienogest has been used in other oral contraceptive pills for over 10 years. Previous attempts to develop an oral contraceptive pill with natural estradiol or estradiol valerate were unsuccessful due to poor cycle control. A novel dynamic-dosing regimen was devised to improve the bleeding pattern. This medication has been shown in several clinical trials to have good contraceptive efficacy and cycle control. Recent studies have also demonstrated that this medication is effective for the treatment of heavy menstrual bleeding. However, compared with other oral contraceptive pills, this medication is associated with a higher frequency of absent withdrawal bleeding. Furthermore, the dynamic dosing regimen requires relatively complex instructions for users who miss pills.",
keywords = "contraception, dienogest, estradiol valerate, heavy menstrual bleeding, menorrhagia",
author = "Elizabeth Micks and Jeffrey Jensen",
year = "2011",
month = "9",
doi = "10.2217/whe.11.49",
language = "English (US)",
volume = "7",
pages = "513--524",
journal = "Women's Health",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Estradiol valerate and dienogest

T2 - A novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding

AU - Micks, Elizabeth

AU - Jensen, Jeffrey

PY - 2011/9

Y1 - 2011/9

N2 - Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an estrogen component that is biologically active as the endogenous estrogen 17β-estradiol. This medication was developed out of efforts to replace the most common estrogen in contraceptive pills, ethinyl estradiol, which is known to be a potent inducer of hepatic protein synthesis. Estradiol valerate has been available since the 1970s in oral and injectable forms indicated for the treatment of menopausal climacteric symptoms. Dienogest has been used in other oral contraceptive pills for over 10 years. Previous attempts to develop an oral contraceptive pill with natural estradiol or estradiol valerate were unsuccessful due to poor cycle control. A novel dynamic-dosing regimen was devised to improve the bleeding pattern. This medication has been shown in several clinical trials to have good contraceptive efficacy and cycle control. Recent studies have also demonstrated that this medication is effective for the treatment of heavy menstrual bleeding. However, compared with other oral contraceptive pills, this medication is associated with a higher frequency of absent withdrawal bleeding. Furthermore, the dynamic dosing regimen requires relatively complex instructions for users who miss pills.

AB - Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an estrogen component that is biologically active as the endogenous estrogen 17β-estradiol. This medication was developed out of efforts to replace the most common estrogen in contraceptive pills, ethinyl estradiol, which is known to be a potent inducer of hepatic protein synthesis. Estradiol valerate has been available since the 1970s in oral and injectable forms indicated for the treatment of menopausal climacteric symptoms. Dienogest has been used in other oral contraceptive pills for over 10 years. Previous attempts to develop an oral contraceptive pill with natural estradiol or estradiol valerate were unsuccessful due to poor cycle control. A novel dynamic-dosing regimen was devised to improve the bleeding pattern. This medication has been shown in several clinical trials to have good contraceptive efficacy and cycle control. Recent studies have also demonstrated that this medication is effective for the treatment of heavy menstrual bleeding. However, compared with other oral contraceptive pills, this medication is associated with a higher frequency of absent withdrawal bleeding. Furthermore, the dynamic dosing regimen requires relatively complex instructions for users who miss pills.

KW - contraception

KW - dienogest

KW - estradiol valerate

KW - heavy menstrual bleeding

KW - menorrhagia

UR - http://www.scopus.com/inward/record.url?scp=80052459557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052459557&partnerID=8YFLogxK

U2 - 10.2217/whe.11.49

DO - 10.2217/whe.11.49

M3 - Article

VL - 7

SP - 513

EP - 524

JO - Women's Health

JF - Women's Health

SN - 1745-5065

IS - 5

ER -